Rh-PDGF vs EMD for Treatment of Intra-bony Defects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05442034 |
Recruitment Status :
Recruiting
First Posted : July 1, 2022
Last Update Posted : August 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intrabony Periodontal Defect | Biological: growth factors to help in regeneration | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Test group will receive rh-PDGF in combination with bone allograft Control group will receive EMD in combination with bone allograft. |
Masking: | Single (Participant) |
Masking Description: | Participants will not know which biologic agent (rh-PDGF or EMD) is being used. |
Primary Purpose: | Treatment |
Official Title: | Rh-PDGF Versus Emdogain for Treatment of Intra-bony Defects |
Actual Study Start Date : | January 1, 2023 |
Estimated Primary Completion Date : | June 30, 2025 |
Estimated Study Completion Date : | June 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: recombinant human platelet derived growth factor (rh-PDGF) in combination with bone allograft
recombinant human platelet derived growth factor is a protein that is found in blood serum. It helps to recruit stem cells into the area to aid in cell differentiation and proliferation. When added to mineralized bone allograft, it stimulates the angiogenesis in the area, and this in turn may increase the outcomes of regeneration.
|
Biological: growth factors to help in regeneration
regenerative therapy |
Active Comparator: Enamel matrix derivatives (EMD) in combination with bone allograft.
Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle. It has been available for decades and has been proved to help in regeneration of intrabony defects when applied into the root surface. When combined with bone allograft, it results in regeneration of intrabony defects.
|
Biological: growth factors to help in regeneration
regenerative therapy |
- Clinical Attachment Changes [ Time Frame: 6 months ]Change in gingival recession and pocket probing depth
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age is 18 years old and older
- Absence of relevant medical conditions
- Availability for 6-month follow-up
- Subjects who recently have received scaling and root planing due to periodontal disease
- Single-rooted and multi-rooted teeth in either the maxilla or the mandible.
- Presence of interdental periodontal pocket with PD ≥ 6 mm associated to an intra-bony component ranged from 3 to 6 mm.
- Non-contained intra-bony defects (1-wall, 2-wall intra-bony defects)
- Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) <20% at surgery
Exclusion Criteria:
- Female patients who are pregnant or planning to be pregnant during the period of the study
- Heavy smokers (>10 cigarettes a day)
- Subjects not willing to comply to the study protocol
- Patients with uncontrolled diabetes (HbA1c >7.5)
- Patients receiving medications that may affect periodontal status in the previous 6 months (e.g., Phenytoin, Alendronate)
- Periapical lesion in the tested sites
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05442034
Contact: Arsalan Danesh, D.D.S | 5612126377 | ad2900@mynsu.nova.edu | |
Contact: Theofilos Koutouzis, DDS, MS | 954-262-1742 | tkoutouzis@nova.edu |
United States, Florida | |
Nova Southeastern University | Recruiting |
Davie, Florida, United States, 33314 | |
Contact: Arsalan Danesh, DDS 561-212-6377 ad2900@mynsu.nova.edu | |
Contact: Cristina Garcia Godoy, DDS 954-262-7388 cgarciag@nova.edu |
Study Director: | Theofilos Koutouzis, DDS, MS | Nova Southeastern University |
Responsible Party: | Nova Southeastern University |
ClinicalTrials.gov Identifier: | NCT05442034 |
Other Study ID Numbers: |
2022-217-NSU |
First Posted: | July 1, 2022 Key Record Dates |
Last Update Posted: | August 15, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Periodontal regeneration Inta-bony defects Enamel matrix derivatives |
Mitogens Mitosis Modulators Molecular Mechanisms of Pharmacological Action |